Synopsis of a roundtable on validating novel therapeutics for multiple myeloma

Clinical Cancer Research

Volumn 12, Issue 22, 2006, Pages 6603-6610

  Dalton, William ^a   Anderson, Kenneth C ^b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; ANTINEOPLASTIC AGENT; BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; FLUOROURACIL; HEAT SHOCK PROTEIN 90 INHIBITOR; HISTONE DEACETYLASE INHIBITOR; IPI 504; JSI 124; MITOXANTRONE; PICROPODOPHYLLIN INHIBITOR OF THE INSULIN LIKE GROWTH FACTOR 1 TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; TUBACIN; VINCRISTINE; ZOLEDRONIC ACID;

APOPTOSIS; BIOLOGICAL MODEL; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RELAPSE; CANCER SCREENING; CANCER THERAPY; CARCINOGENESIS; CELL HETEROGENEITY; CLINICAL TRIAL; COCULTURE; DRUG SCREENING; DRUG SYNTHESIS; EPSTEIN BARR VIRUS; HUMAN; IN VITRO STUDY; MICROENVIRONMENT; MULTIPLE MYELOMA; MUTATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR MODEL; XENOGRAFT;

ALGORITHMS; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE; DRUG DESIGN; GENETIC HETEROGENEITY; HUMANS; MICE; MODELS, ANIMAL; MODELS, BIOLOGICAL; MULTIPLE MYELOMA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33845285214     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-1489     Document Type: Review

References (44)

1. Zaidi AA, Vesole DH. Multiple myeloma: an old disease with new hope for the future. CA Cancer J Clin 2001;51:273-85; quiz 86-9.
2. Martinelli G, Tosi P, Ottaviani E, Soverini S, Tura S. Molecular therapy for multiple myeloma. Haematologica 2001;86:908-17.
3. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004;351:1860-73.
4. Anderson KC. Targeted therapy for multiple myeloma. Semin Hematol 2001;38:286-94.
5. Dalton WS, Bergsagel PL, Kuehl WM, Anderson KC, Harousseau JL. Multiple myeloma. Hematology (Am Soc Hematol Educ Program) 2001;1:157-77.
6. Kumar S, Fonseca R, Dispenzieri A, et al. Bone marrow angiogenesis in multiple myeloma: effect of therapy. Br J Haematol 2002;119:665-71.
7. Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 1999;93:1658-67.
8. Nefedova Y, Landowski TH, Dalton WS. Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms. Leukemia 2003;17:1175-82.
9. Shain KH, Landowski TH, Dalton WS. Adhesion-mediated intracellular redistribution of c-Fas-associated death domain-like IL-1-converting enzyme-like inhibitory protein-long confers resistance to CD95-induced apoptosis in hematopoietic cancer cell lines. J Immunol 2002;168:2544-53.
10. Matsuoka Y, Moore GE, Yagi Y, Pressman D. Production of free light chains of immunoglobulin by a hematopoietic cell line derived from a patient with multiple myeloma. Proc Soc Exp Biol Med 1967;125:1246-50.
11. Carini C, Hudspith BN, Brostoff J. Effect of prostaglandins and cyclic nucleotides on growth and immunoglobulin secretion of two IgE myeloma cell lines. Br J Cancer 1981;43:257-60.
12. Bergsagel PL, Kuehl WM. Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol 2005;23:6333-8.
13. Kuehl WM, Bergsagel PL. Early genetic events provide the basis for a clinical classification of multiple myeloma. Hematology (Am Soc Hematol Educ Program) 2005;1:346-52.
14. Bergsagel PL, Kuehl WM. Critical roles for immunoglobulin translocations and cyclin D dysregulation in multiple myeloma. Immunol Rev 2003;194:96-104.
15. Dalton WS, Durie BG, Alberts DS, Gerlach JH, Cress AE. Characterization of a new drug-resistant human myeloma cell line that expresses P-glycoprotein. Cancer Res 1986;46:5125-30.
16. Hazlehurst LA, Foley NE, Gleason-Guzman MC, et al. Multiple mechanisms confer drug resistance to mitoxantrone in the human 8226 myeloma cell line. Cancer Res 1999;59:1021-8.
17. Bellamy WT, Dalton WS, Gleason MC, Grogan TM, Trent JM. Development and characterization of a melphalan-resistant human multiple myeloma cell line. Cancer Res 1991;51:995-1002.
18. Greenstein S, Krett NL, Kurosawa Y, et al. Characterization of the MM.1 human multiple myeloma (MM) cell lines: a model system to elucidate the characteristics, behavior, and signaling of steroid-sensitive and -resistant MM cells. Exp Hematol 2003;31:271-82.
19. Oshiro MM, Landowski TH, Catlett-Falcone R, et al. Inhibition of JAK kinase activity enhances Fas-mediated apoptosis but reduces cytotoxic activity of topoisomerase II inhibitors in U266 myeloma cells. Clin Cancer Res 2001;7:4262-71.
20. Nefedova Y, Cheng P, Alsina M, Dalton WS, Gabrilovich DI. Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines. Blood 2004;103:3503-10.
21. Alici E, Konstantinidis KV, Aints A, Dilber MS, Abedi-Valugerdi M. Visualization of 5T33 myeloma cells in the C57BL/KaLwRij mouse: establishment of a new syngeneic murine model of multiple myeloma. Exp Hematol 2004;32:1064-72.
22. Vanderkerken K, Asosingh K, Willems A, et al. The 5T2MM murine model of multiple myeloma: maintenance and analysis. Methods Mol Med 2005;113:191-205.
23. Yaccoby S, Barlogie B, Epstein J. Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations. Blood 1998;92:2908-13.
24. Tassone P, Neri P, Kutok JL, et al. A SCID-hu in vivo model of human Waldenstrom macroglobulinemia. Blood 2005;106:1341-5.
25. Tassone P, Neri P, Carrasco DR, et al. A clinically relevant SCID-hu in vivo model of human multiple myeloma. Blood 2005;106:713-6.
26. Linden M, Kirchhof N, Kvitrud M, Van Ness B. ABL-MYC retroviral infection elicits bone marrow plasma cell tumors in Bcl-X(L) transgenic mice. Leuk Res 2005;29:435-44.
27. Mitsiades CS, Mitsiades NS, Bronson RT, et al. Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: biologic and clinical implications. Cancer Res 2003;63:6689-96.
28. Asosingh K, Radl J, Van Riet I, Van Camp B, Vanderkerken K. The 5TMM series: a useful in vivo mouse model of human multiple myeloma. Hematol J 2000;1:351-6.
29. Croucher PI, De Hendrik R, Perry MJ, et al. Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. J Bone Miner Res 2003;18:482-92.
30. Menu E, Braet F, Timmers M, Van Riet I, Van Camp B, Vanderkerken K. The F-actin content of multiple myeloma cells as a measure of their migration. Ann N Y Acad Sci 2002;973:124-36.
31. Menu E, Jernberg-Wiklund H, Stromberg T, et al. Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: an in vitro and in vivo study in the 5T33MM mouse model. Blood 2006;107:655-60.
32. Mitsiades CS, Mitsiades N. CC-5013 (Celgene). Curr Opin Investig Drugs 2004;5:635-47.
33. Yata K, Yaccoby S. The SCID-rab model: a novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells. Leukemia 2004;18:1891-7.
34. Hamasaki M, Hideshima T, Tassone P, et al. Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo. Blood 2005;105:4470-6.
35. Hideshima T, Chauhan D, Richardson P, Anderson KC. Identification and validation of novel therapeutic targets for multiple myeloma. J Clin Oncol 2005;23:6345-50.
36. Yanamandra N, Colaco NM, Parquet NA, et al. Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia. Clin Cancer Res 2006;12:591-9.
37. Blaskovich MA, Sun J, Cantor A, Turkson J, Jove R, Sebti SM. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res 2003;63:1270-9.
38. Haggarty SJ, Koeller KM, Wong JC, Grozinger CM, Schreiber SL. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc Natl Acad Sci U S A 2003;100:4389-94.
39. Schreiber SL. Small molecules: the missing link in the central dogma. Nat Chem Biol 2005;1:64-6.
40. Hideshima T, Bradner JE, Wong J, et al. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci U S A 2005;102:8567-72.
41. Buzzeo R, Enkemann S, Nimmanapalli R, et al. Characterization of a R115777-resistant human multiple myeloma cell line with cross-resistance to PS-341. Clin Cancer Res 2005;11:6057-64.
42. Chen Q, Van der Sluis PC, Boulware D, Hazlehurst LA, Dalton WS. The FA/BRCA pathway is involved in melphalan-induced DNA interstrand cross-link repair and accounts for melphalan resistance in multiple myeloma cells. Blood 2005;106:698-705.
43. Matsui W, Huff CA, Wang Q, et al. Characterization of clonogenic multiple myeloma cells. Blood 2004;103:2332-6.
44. Matsui W. Expanding the toolbox of myeloma biology. Haematologica 2005;90:1448.